Free tool
FAERS Monitor: Perjeta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125409 or its brand name (Perjeta, Pertuzumab). Reports on generic versions are filed under their own applications.
Reports
27,608
Serious
23,433
85% of reports
Hospitalization
9,313
Death reported
2,728
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea3,873
- off label use2,424
- nausea1,996
- fatigue1,951
- myelosuppression1,628
- alopecia1,587
- disease progression1,380
- vomiting1,323
- dyspnoea1,213
- neuropathy peripheral1,146
- death1,119
- pyrexia1,078
- neutropenia1,027
- rash963
- anaemia901
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2009 | 6 |
| 2010 | 19 |
| 2011 | 22 |
| 2012 | 128 |
| 2013 | 679 |
| 2014 | 734 |
| 2015 | 922 |
| 2016 | 1,184 |
| 2017 | 1,909 |
| 2018 | 2,175 |
| 2019 | 2,290 |
| 2020 | 2,531 |
| 2021 | 2,951 |
| 2022 | 2,699 |
| 2023 | 2,753 |
| 2024 | 3,065 |
| 2025 | 2,025 |
| 2026 | 1,515 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,551 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelosuppressionSignal | 1,628 | 36.0 | 34.3 | 52,979 |
| neuropathy peripheralSignal | 1,146 | 9.3 | 8.8 | 8,392 |
| disease progressionSignal | 1,380 | 9.0 | 8.5 | 9,716 |
| alopeciaSignal | 1,587 | 6.2 | 5.9 | 6,923 |
| neutropeniaSignal | 1,027 | 5.8 | 5.5 | 4,061 |
| diarrhoeaSignal | 3,873 | 4.6 | 4.5 | 11,158 |
| anaemiaSignal | 901 | 3.6 | 3.4 | 1,706 |
| pyrexiaSignal | 1,078 | 2.4 | 2.2 | 871 |
| vomitingSignal | 1,323 | 2.1 | 2.0 | 826 |
| off label useSignal | 2,424 | 2.1 | 2.0 | 1,476 |
| nausea | 1,996 | 1.9 | 1.8 | 917 |
| fatigue | 1,951 | 1.9 | 1.8 | 877 |
| rash | 963 | 1.7 | 1.6 | 272 |
| dyspnoea | 1,213 | 1.6 | 1.5 | 305 |
| death | 1,119 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.